ATYR

Atyr Pharma Inc

6.11

Nov 13 • 3:59 PM ET -0.11 (-1.69%)

6.01

Aftermarket • 7:38 PM ET -0.09 (-1.56%)

Healthcare Biotechnology USA Nano NASD

Peers: TVRD PLRX SVRA ROIV GOSS INSM KYTX UTHR LQDA CPIX

| Held by: VTI VXF

Scroll to Statements

Index	-
Market Cap	14.97M
Enterprise Value	-23.05M
Income	-53.32M
Sales	0.00M
Book/sh	13.53
Cash/sh	19.88
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	58
IPO	May 07, 2015

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	0.45
P/C	0.31
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	3.05
Current Ratio	3.05
Debt/Eq	0.32
LT Debt/Eq	0.28
Option/Short	No / Yes

EPS (ttm)	-21.74
EPS next Y	-12.18
EPS next Q	-6.01
EPS this Y	37.13%
EPS next Y	39.46%
EPS next 5Y	25.66%
EPS past 3/5Y	20.65% 14.76%
Sales past 3/5Y	-73.65% -55.14%
EPS Y/Y TTM	34.89%
Sales Y/Y TTM	-100.00%
EPS Q/Q	29.87%
Sales Q/Q	-100.00%
Earnings	Nov 05 AMC
EPS/Sales Surpr.	-18.19% -

Insider Own	-
Insider Trans	-
Inst Own	26.95%
Inst Trans	-
ROA	-64.07%
ROE	-93.37%
ROIC	-122.49%
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	-3.36%
SMA50	-40.85%
SMA200	-73.54%
Trades

Shs Outstand	2.51M
Shs Float	-
Short Float	-
Short Ratio	2.71
Short Interest	0.29M
52W High	44.40 -86.25%
52W Low	4.07 50.07%
Volatility	15.24% 15.50%
ATR (14)	0.99
RSI (14)	37.35
Beta	1.03
Rel Volume	0.35
Avg Volume	108.17K
Volume	38,196

Perf Week	-3.86%
Perf Month	-16.96%
Perf Quarter	-70.59%
Perf Half Y	-69.72%
Perf YTD	-80.51%
Perf Year	-78.61%
Perf 3Y	-86.31%
Perf 5Y	-98.25%
Perf 10Y	-99.65%
Recom	2.43
Target Price	15.00
Prev Close	6.21
Price	6.11
Change %	-1.69%

Consensus

Buy

Avg. Price Target

$15.00

Implied Upside

+145.7%

Analysts13incl. previous ratings

Rating Distribution5 Buy · 7 Hold · 1 Sell

Date	Action	Analyst	Rating Change	Price Target Change	Implied Upside
Sep 16, 2025	Downgrade	RRBC Capital Mkts	Outperform → Sector Perform	$1.50	-75.4%
Sep 15, 2025	Downgrade	WWells Fargo	Overweight → Equal Weight	$1	-83.6%
Sep 15, 2025	Downgrade	LLeerink Partners	Outperform → Market Perform	$1	-83.6%
Sep 15, 2025	Downgrade	HH.C. Wainwright	Buy → Neutral
Sep 15, 2025	Downgrade	CCantor Fitzgerald	Overweight → Neutral
Feb 18, 2025	Initiated	LLeerink Partners	Outperform	$16	+162.1%
Jan 06, 2025	Initiated	CCantor Fitzgerald	Overweight
Oct 04, 2024	Initiated	WWells Fargo	Overweight	$17	+178.5%
Sep 05, 2024	Initiated	JJefferies	Buy	$9	+47.4%
Jul 05, 2023	Downgrade	OOppenheimer	Outperform → Perform
Oct 12, 2021	Initiated	RRBC Capital Mkts	Outperform	$22	+260.4%
Sep 21, 2021	Initiated	PPiper Sandler	Overweight	$19	+211.2%
May 10, 2021	Initiated	LLaidlaw	Buy	$18	+194.8%
Aug 17, 2020	Upgrade	HH.C. Wainwright	Neutral → Buy	$13	+112.9%
Mar 04, 2020	Initiated	RROTH Capital	Buy	$15	+145.7%
Mar 02, 2020	Initiated	OOppenheimer	Outperform	$8	+31.0%
Feb 14, 2018	Downgrade	JJP Morgan	Neutral → Underweight
Sep 07, 2017	Initiated	PPiper Jaffray	Overweight	$7	+14.7%
Dec 13, 2016	Downgrade	JJP Morgan	Overweight → Neutral
Dec 16, 2015	Initiated	CCitigroup	Neutral

Nov-11-26 08:00AM	aTyr Pharma to Participate in Upcoming Investor Conferences (GlobeNewswire) -10.45%
Nov-05-26 04:26PM	Atyr Pharma: Q3 Earnings Snapshot (Associated Press) +5.31%
04:01PM	aTyr Pharma Announces Third Quarter 2026 Results and Provides Corporate Update (GlobeNewswire)
Oct-29-26 08:00AM	aTyr Pharma Announces Publication of Results from the Phase 3 EFZO-FIT Study of Efzofitimod in Pulmonary Sarcoidosis in The Lancet Respiratory Medicine (GlobeNewswire)
Oct-27-26 09:00AM	aTyr Pharma Announces One-for-40 Reverse Stock Split (GlobeNewswire) -19.17%
07:00AM	Loading…
Oct-19-26 07:00AM	aTyr Pharma Announces Research Collaboration with Montefiore Einstein (GlobeNewswire)
Oct-13-26 08:00AM	aTyr Pharma Announces Publication Demonstrating Anti-Fibrotic Effects of ATYR0101 in the Journal of Biological Chemistry (GlobeNewswire) -6.38%
Sep-24-26 10:59AM	aTyr Pharma FDA Alignment Sets Protocol for Phase 3 Efzofitimod Study in Pulmonary Sarcoidosis (InvestorsHub) -10.02%
06:00AM	aTyr Pharma Announces Alignment with FDA on Phase 3 Study of Efzofitimod in Pulmonary Sarcoidosis (GlobeNewswire)
Sep-01-26 04:36PM	aTyr Pharma Provides Update on Timing of Regulatory Response for Planned Phase 3 Study of Efzofitimod in Pulmonary Sarcoidosis (GlobeNewswire) -10.38%
Aug-07-26 04:21PM	Atyr Pharma: Q2 Earnings Snapshot (Associated Press)
04:01PM	aTyr Pharma Announces Second Quarter 2026 Results, Program Prioritization and Corporate Restructuring to Support Efzofitimod Program in ILD (GlobeNewswire)
Jul-15-26 08:00AM	aTyr Pharma to Present Subgroup Analysis of Phase 3 EFZO-FIT Study of Efzofitimod in Pulmonary Sarcoidosis at WASOG 2026 (GlobeNewswire) +9.94%
Jul-13-26 09:12AM	What It Means To Hold Moderna Stock In A Crash (Trefis) -7.40%
May-15-26 08:06AM	Atyr Pharma: Q1 Earnings Snapshot (Associated Press) -9.98%
08:00AM	Loading…
08:00AM	aTyr Pharma Announces First Quarter 2026 Results and Provides Corporate Update (GlobeNewswire)
May-13-26 04:01PM	aTyr Pharma to Participate in Upcoming Investor Conferences (GlobeNewswire) -25.33% +41.42%
May-11-26 04:01PM	aTyr Pharma Provides Regulatory and Clinical Update for Efzofitimod in Pulmonary Sarcoidosis Following FDA Type C Meeting (GlobeNewswire) -44.20%
Mar-05-26 04:10PM	Atyr Pharma: Q4 Earnings Snapshot (Associated Press Finance) -6.45% -8.68%
04:01PM	aTyr Pharma Announces Fourth Quarter and Full Year 2025 Results and Provides Corporate Update (GlobeNewswire)
Feb-20-26 04:01PM	aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Feb-18-26 08:00AM	aTyr Pharma to Present at the Leerink Partners Global Healthcare Conference (GlobeNewswire)
Feb-03-26 08:00AM	aTyr Pharma Announces Scheduling of FDA Type C Meeting to Discuss Efzofitimod Program in Pulmonary Sarcoidosis (GlobeNewswire)
Nov-25-25 04:08PM	aTyr Pharma (ATYR) Posts Wider-Than-Expected Loss as Investor Litigation Over Key Drug's Efficacy Moves Forward -- Hagens Berman (PR Newswire)
Nov-20-25 01:27PM	aTyr Pharma (ATYR) Posts Wider-Than-Expected Loss as Investor Litigation Over Key Drug's Efficacy Moves Forward -- Hagens Berman (Newsfile)
Nov-18-25 02:03PM	ATYR INVESTOR NOTICE: New aTyr Pharma, Inc. (ATYR) Securities Class Filed; Class Period Significantly Enlarged -- Hagens Berman (PR Newswire)
Nov-11-25 09:23AM	aTyr Pharma, Inc. (ATYR) Failed Drug Trial Spurs Securities Lawsuit; Class Period Significantly Enlarged -- Hagens Berman (PR Newswire)
Nov-10-25 08:00AM	aTyr Pharma to Present at Piper Sandler 37th Annual Healthcare Conference (GlobeNewswire)
Nov-06-25 04:48PM	Atyr Pharma: Q3 Earnings Snapshot (Associated Press Finance) -5.35% +6.05%
04:01PM	aTyr Pharma Announces Third Quarter 2025 Results and Provides Corporate Update (GlobeNewswire)
08:35AM	Loading…
08:35AM	Investors in aTyr Pharma, Inc. (ATYR): Protect Your Rights - Contact Levi & Korsinsky Before December 8, 2025 (Newsfile)
Oct-23-25 01:11PM	aTyr Pharma, Inc.'s (ATYR) Failed Drug Trial Spurs Securities Lawsuit -- Hagens Berman (Newsfile)
Oct-21-25 09:00AM	Shareholders of aTyr Pharma, Inc. Should Contact Levi & Korsinsky Before December 8, 2025 to Discuss Your Rights - ATYR (PR Newswire)
Oct-15-25 02:05PM	aTyr Pharma, Inc.'s (ATYR) Failed Drug Trial Spurs Securities Lawsuit -- Hagens Berman (Business Wire)
Oct-14-25 08:20AM	aTyr Pharma, Inc.'s (ATYR) Failed Drug Trial Spurs Securities Lawsuit -- Hagens Berman (PR Newswire) +7.68%
Oct-10-25 07:06PM	aTyr Pharma, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights ATYR (Business Wire) +11.23% -8.89%
Oct-09-25 10:18PM	aTyr Pharma, Inc.'s (ATYR) Failed Drug Trial Spurs Securities Lawsuit -- Hagens Berman (PR Newswire)
Sep-30-25 05:30AM	aTyr Pharma Presents Additional Findings from Phase 3 EFZO-FIT Study in Late-Breaking Oral Abstract at the European Respiratory Society (ERS) Congress 2025 (GlobeNewswire) -9.28%
Sep-23-25 09:22AM	aTyr Pharma, Inc. (ATYR) Faces Investor Scrutiny After EFZO-FIT Study Failure Drives Shares 80% Lower -- Hagens Berman (PR Newswire) -5.70%
Sep-17-25 09:03AM	aTyr Pharma, Inc. (ATYR) Faces Investor Scrutiny After EFZO-FITÔ Study Failure Drives Shares 80% Lower -- Hagens Berman (PR Newswire) -5.09%
Sep-16-25 07:20AM	aTyr Pharma stock crashes on Phase III pulmonary sarcoidosis fail (Clinical Trials Arena) +6.40%
Sep-15-25 08:11AM	ATyr shares plunge on trial miss in inflammatory lung disease (BioPharma Dive) -83.17%
07:30AM	aTyr Pharma Announces Topline Results from Phase 3 EFZO-FIT Study of Efzofitimod in Pulmonary Sarcoidosis (GlobeNewswire)
Sep-11-25 10:15AM	1 Small-Cap Biotech Stock Poised for a Breakout (Motley Fool)
03:31AM	Lead Therapy Trial Fuels aTyr Pharma's (ATYR) Promising Upside, Leerink Stays Bullish (Insider Monkey)
Sep-08-25 12:30AM	Jefferies Raises Price Target for aTyr Pharma (ATYR) Ahead of Study Results (Insider Monkey)
Sep-05-25 04:00PM	aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-02-25 10:30AM	BC-Most Active Stocks (Associated Press Finance) +5.02%
Aug-20-25 12:22AM	ATyr Pharma Rated as Overweight at Cantor Fitzgerald on Efzofitimod Expectations (Insider Monkey) +5.58%
Aug-07-25 04:41PM	Atyr Pharma: Q2 Earnings Snapshot (Associated Press Finance)
04:00PM	aTyr Pharma Announces Second Quarter 2025 Results and Provides Corporate Update (GlobeNewswire)
Jul-31-25 10:40AM	Martin Shkreli Is Shorting This Strong Buy Penny Stock. How Should You Play Shares Here? (Barchart)
Jul-22-25 08:00AM	aTyr Pharma Announces Last Patient Visit in Phase 3 EFZO-FIT Study of Efzofitimod in Patients with Pulmonary Sarcoidosis (GlobeNewswire) -8.23%
Jun-26-25 08:00AM	aTyr Pharma to be Added to the Russell 2000 and Russell 3000 Indexes (GlobeNewswire)
Jun-04-25 08:00AM	aTyr Pharma Announces Findings from Interim Analysis of Ongoing Phase 2 EFZO-CONNECT Study of Efzofitimod in Systemic Sclerosis-Related Interstitial Lung Disease (SSc-ILD) (GlobeNewswire)
May-21-25 11:21AM	aTyr Pharma, Inc. (ATYR): Analysts See 485% Upside Potential (Insider Monkey) +7.45%
May-20-25 08:00AM	aTyr Pharma to Present at Upcoming Investor Conferences (GlobeNewswire)
May-19-25 08:00AM	aTyr Pharma Presents Three Posters on Efzofitimod at the American Thoracic Society (ATS) 2025 International Conference (GlobeNewswire) +5.20%
May-16-25 04:01PM	aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +9.00%
May-14-25 08:00AM	aTyr Pharma Advances ATYR0101 to IND Candidate Stage for Pulmonary Fibrosis (GlobeNewswire) -8.46%
May-09-25 08:32AM	Is aTyr Pharma, Inc. (ATYR) the Low Risk High Reward Stock Set to Triple by 2030? (Insider Monkey)
May-07-25 04:01PM	aTyr Pharma Announces First Quarter 2025 Results and Provides Corporate Update (GlobeNewswire) +5.70%
Apr-29-25 08:00AM	aTyr Pharma Presents Preclinical Data for NRP2-Targeting Antibody ATYR2810 at the American Association for Cancer Research (AACR) Annual Meeting 2025 (GlobeNewswire)
Apr-03-25 08:00AM	aTyr Pharma to Participate in April Investor Conferences (GlobeNewswire) -5.74%
Mar-27-25 04:00PM	aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
12:27PM	Is aTyr Pharma (ATYR) The Hot Biotech Stock Under $5? (InsiderMonkey)
Mar-26-25 08:00AM	aTyr Pharma Announces the Appointment of Dalia R. Rayes as Head of Commercial, Global Efzofitimod Franchise (GlobeNewswire) -7.16%
Mar-19-25 09:40AM	Is aTyr Pharma (ATYR) Stock Outpacing Its Medical Peers This Year? (Zacks)
Mar-14-25 03:11AM	aTyr Pharma Inc (ATYR) Q4 2024 Earnings Call Highlights: Strong Cash Position and Promising ... (GuruFocus.com)
Mar-13-25 04:01PM	aTyr Pharma Announces Fourth Quarter and Full Year 2024 Results and Provides Corporate Update (GlobeNewswire) +12.39%
Mar-12-25 04:00PM	aTyr Pharma Announces Publication Demonstrating Efzofitimod's Immunomodulatory Activity in Science Translational Medicine (GlobeNewswire) +15.64%
Mar-06-25 04:02PM	aTyr Pharma Announces Fourth Positive DSMB Review for Efzofitimod in Phase 3 EFZO-FIT Study in Pulmonary Sarcoidosis (GlobeNewswire) +10.39%
Mar-04-25 08:00AM	aTyr Pharma to Webcast Conference Call Reporting Fourth Quarter and Full Year End 2024 Financial Results (GlobeNewswire) -8.18%
Feb-24-25 08:00AM	aTyr Pharma to Present at the Leerink Partners Global Healthcare Conference (GlobeNewswire) -11.34%
Jan-29-25 08:00AM	aTyr Pharma to Present Three Posters for Efzofitimod at the American Thoracic Society (ATS) 2025 International Conference (GlobeNewswire)
Dec-17-24 08:00AM	aTyr Pharma to Present at the 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-12-24 04:00PM	aTyr Pharma Announces the Appointment of Eric Benevich to its Board of Directors (GlobeNewswire)
Dec-10-24 08:00AM	aTyr Pharma Announces Third Positive DSMB Review for Efzofitimod in Phase 3 EFZO-FIT Study in Pulmonary Sarcoidosis (GlobeNewswire) -6.80%
Dec-09-24 08:00AM	aTyr Pharma to Present Preclinical Research Demonstrating Anti-Fibrotic Effects of ATYR0101 in Lung and Kidney Fibrosis at Keystone Symposia on Fibrosis (GlobeNewswire) +5.06%
Nov-15-24 08:00AM	aTyr Pharma to Present Posters on tRNA Synthetase Candidate ATYR0101 at Keystone Symposia on Fibrosis (GlobeNewswire) -8.93%
Nov-07-24 04:01PM	aTyr Pharma Announces Third Quarter 2024 Results and Provides Corporate Update (GlobeNewswire)
Oct-31-24 08:00AM	aTyr Pharma to Present at Upcoming Investor Conferences (GlobeNewswire)
Oct-14-24 08:00AM	aTyr Pharma to Present at the LD Micro Main Event XVII in October (Newsfile)
Oct-08-24 08:00AM	aTyr Pharma's Lead Therapeutic Candidate Efzofitimod for Pulmonary Sarcoidosis to be Featured in Best of CHEST Journals at CHEST 2024 Annual Meeting (GlobeNewswire)
Oct-02-24 08:00AM	aTyr Pharma Announces Publication Demonstrating Efficacy of Efzofitimod in Pulmonary Sarcoidosis in the European Respiratory Journal (GlobeNewswire)
Aug-21-24 08:00AM	aTyr Pharma to Participate in September Investor Conferences (GlobeNewswire)
Aug-13-24 04:00PM	aTyr Pharma Announces Second Quarter 2024 Results and Provides Corporate Update (GlobeNewswire) +6.32%
Aug-06-24 08:00AM	aTyr Pharma Announces Appointment of Jayant Aphale, PhD, as Vice President of Technical Operations (GlobeNewswire)
Jul-30-24 08:00AM	aTyr Pharma Announces Research Study with Stanford Medicine (GlobeNewswire) -6.60%
Jul-22-24 08:00AM	aTyr Pharma Completes Enrollment in Global Pivotal Phase 3 EFZO-FIT Study of Efzofitimod in Pulmonary Sarcoidosis (GlobeNewswire) +13.41%
Jun-18-24 09:40AM	Is aTyr Pharma (ATYR) Outperforming Other Medical Stocks This Year? (Zacks) -6.78%
Jun-10-24 10:52AM	ATYR Stock Earnings: aTyr Pharma Beats EPS for Q2 2023 (InvestorPlace)
Jun-05-24 03:17PM	Millionaire Makers: 7 Stocks You Can Buy for $2 That Can 10X by 2025 (InvestorPlace)
Jun-03-24 08:00AM	aTyr Pharma Announces Nasdaq Stock Ticker Symbol Change from LIFE to ATYR (GlobeNewswire) +6.94%
May-24-24 04:00PM	aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
May-15-24 07:00AM	aTyr Pharma to Present Poster Describing Efzofitimod's Mechanism of Action at the American Thoracic Society 2024 International Conference (GlobeNewswire) +5.22%
May-14-24 08:00AM	aTyr Pharma Announces Second Positive DSMB Review for Efzofitimod in Phase 3 EFZO-FIT Study in Pulmonary Sarcoidosis (GlobeNewswire) +7.06%
May-06-24 08:00AM	aTyr Pharma to Present at Upcoming Investor Conferences (GlobeNewswire)
May-02-24 09:58PM	LIFE Stock Earnings: aTyr Pharma Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace)
04:15PM	Atyr Pharma: Q1 Earnings Snapshot (Associated Press Finance)

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
SCHIMMEL PAUL	Director	May 27 '26	Buy	0.50	100,000	49,630	779,143	May 28 04:12 PM
Shukla Sanjay	President and CEO	Feb 04 '26	Sale	0.98	3,745	3,655	153,553	Feb 04 07:17 PM
Broadfoot Jill Marie	Chief Financial Officer	Feb 04 '26	Sale	0.98	1,558	1,521	37,296	Feb 04 07:15 PM
DENYES NANCY	General Counsel	Feb 04 '26	Sale	0.98	1,118	1,091	33,124	Feb 04 07:12 PM

aTyr Pharma, Inc. engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.

M.S.Dr. Sanjay S. Shukla M.D.

Chief Financial OfficerMr. Brandon Yaras

Director of Investor Relations & Corporate CommunicationsMs. Ashlee Dunston

VP of Human ResourceMs. Danielle Campbell

Vice President of ResearchDr. Leslie Nangle Ph.D.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

All the Features.Half the Price.

ATYR

Atyr Pharma Inc

Upgrade your Finviz experience

All the Features.
Half the Price.